Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
- Ixazomib Granted Accelerated Assessment in EU: Takeda
July 29, 2015
- Takeda, DNDi Partner for Development of Visceral Leishmaniasis Treatment
July 29, 2015
- Carfilzomib Approved for Combination Use in US: Ono
July 29, 2015
- Delving into Securities Filings - 1: Average Salary of 25 Makers Up 4.9% in 5 Years, Generic Players Close in on Top-Tier Firms
July 29, 2015
- Eisai Files for Regulatory Approval of Perampanel in Japan
July 28, 2015
- Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
- Toho to Narrow Down Recommended Drug Makers, Will Need to Devise Specific Marketing Policy for Generics: Pres. Edahiro
July 27, 2015
- Fujifilm, Kyowa Kirin JV to Develop Avastin Biosimilar with AZ
July 27, 2015
- Kyowa Kirin Ups Earnings Outlook on Nesp, G-Lasta
July 27, 2015
- Sumitomo Dainippon, Kyoto Univ., Hitachi to Collaborate on Regenerative Medicine for Parkinson’s Disease Utilizing iPS Cells
July 27, 2015
- Chugai Revenues Up 8.2% on Cancer Drugs, Actemra
July 24, 2015
- Toho to Differentiate Itself through Customer Support Rather than Prices: Pres.
July 24, 2015
- Astellas, AIST Partner Up for Joint Research for IT Drug-Discovery Technologies
July 24, 2015
- Kyowa Kirin to File for Regulatory Approval of Psoriasis Treatment Brodalumab
July 24, 2015
- EU Approves Opdivo for Squamous NSCLC: BMS
July 23, 2015
- Cell Transplantation Using iPS Cell-Derived Renal Progenitors Effective for Acute Kidney Injury in Mice: Kyoto Univ., Astellas
July 23, 2015
- PIII Study of Opdivo in Renal Cell Carcinoma Ends Early Based on Favorable Results: Ono, BMS
July 23, 2015
- JCR, Eisai Collaborate for Blood-Brain Barrier Penetration Technology
July 22, 2015
- Ono Files Opdivo for Non-Squamous NSCLC
July 22, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…